News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How This Small Washington Biotech Stands To Outperform Rivals Amgen (AMGN), Eli Lilly (LLY) And Teva (TEVA) In Migraine Drugs



6/9/2017 6:04:01 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Wall Street is undervaluing Alder Biopharmaceuticals (ALDR) which stands to outperform larger rivals Amgen, Eli Lilly and Teva Pharmaceutical in migraine drugs, an analyst said Thursday ahead of a key conference on headache treatments.

Needham analyst Danielle Brill maintained her buy rating and 36 price target on Alder stock. On the stock market today, Alder stock climbed 1.2% to 16.55. Alder is set to present data this weekend from a Phase 2 clinical trial of a treatment for frequent episodic migraines. Phase 3 data from the trial dubbed Promise-1 is expected by the end of the month.

Read at BioSpace.com


comments powered by Disqus
   
Migraine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES